BiotechTube

Ciprofloxacin DPI (BAYQ3939) + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis

Trial Timeline

May 2, 2013 → Mar 9, 2016

NCT ID
NCT01764841

About Ciprofloxacin DPI (BAYQ3939) + Placebo

Ciprofloxacin DPI (BAYQ3939) + Placebo is a phase 3 stage product being developed by Novartis for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01764841. Target conditions include Bronchiectasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01764841Phase 3Completed

Competing Products

20 competing products in Bronchiectasis

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
77
AZD9668 + PlaceboAstraZenecaPhase 2
52
AZD5069 + PlaceboAstraZenecaPhase 2
52
AZD0292AstraZenecaPhase 2
52
TIP + TIP and placebo + PlaceboNovartisPhase 2
52
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
23
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
77
QBW251 + PlaceboNovartisPhase 2
52
Ciprofloxacin (Cipro, BAYQ3939) + PlaceboNovartisPhase 2
52
AZLI + PlaceboGilead SciencesPhase 3
76
Aztreonam lysineGilead SciencesApproved
84
AZLIGilead SciencesPhase 2
51
AZLI + PlaceboGilead SciencesPhase 3
76
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
51
CSL787 + PlaceboCSLPhase 1
32
CSL787 + PlaceboCSLPhase 2
51
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
74
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
49
Group A + Group BBayerPre-clinical
20
BAY85-8501 + PlaceboBayerPhase 2
49

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85